WP9QY 是一种靶向 TNFα 和 RANKL 的抑制剂,可阻断 TNFα-TNFR1 相互作用并抑制 TNFα 介导的细胞凋亡 (apoptosis)、毒性及骨破坏作用,同时抑制破骨细胞生成并促进成骨细胞分化,还能诱导软骨细胞增殖及糖胺聚糖生成,并与 TGF-β3 协同促进软骨形成,此外可通过关节内注射有效修复兔全层关节软骨缺损,并能抑制甲基汞诱导的小鼠脑切片中 NeuN 阳性细胞的减少,因此可应用于甲基汞诱导的神经元死亡、软骨损伤、骨关节炎及骨丢失等相关疾病的研究中。
产品编号: MS-Z48080 纯度: 99.79% CAS No.: 199999-60-5 分子式: C58H71N11O15S2 分子量: 1226.38
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
500μg
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

WP9QY 是一种靶向 TNFα 和 RANKL 的抑制剂,可阻断 TNFα-TNFR1 相互作用并抑制 TNFα 介导的细胞凋亡 (apoptosis)、毒性及骨破坏作用,同时抑制破骨细胞生成并促进成骨细胞分化,还能诱导软骨细胞增殖及糖胺聚糖生成,并与 TGF-β3 协同促进软骨形成,此外可通过关节内注射有效修复兔全层关节软骨缺损,并能抑制甲基汞诱导的小鼠脑切片中 NeuN 阳性细胞的减少,因此可应用于甲基汞诱导的神经元死亡、软骨损伤、骨关节炎及骨丢失等相关疾病的研究中。

生物实验数据

生物活性 WP9QY is an inhibitor targeting TNFα and RANKL that blocks TNFα-TNFR1 interaction and inhibits TNFα-mediated apoptosis, toxicity, and bone destruction, while also inhibiting osteoclastogenesis and promoting osteoblast differentiation, inducing chondrocyte proliferation and glycosaminoglycan production, and synergizing with TGF-β3 to promote chondrogenesis; furthermore, it effectively repairs full-thickness articular cartilage defects in rabbits via intra-articular injection and inhibits methylmercury-induced reduction of NeuN-positive cells in mouse brain slices, and can therefore be applied in research on methylmercury-induced neuronal death, cartilage injury, osteoarthritis, and bone loss, among other related diseases.
体外研究
(In Vitro)

WP9QY 功能化 PEG 水凝胶 (100-250 μM; 24 h TNFα 暴露, NGF 分化培养 6 d) 可保护分化 PC12 细胞免受 50 ng/mL 人源 TNFα 诱导的细胞凋亡,维持细胞活力并阻止 caspase 3/7 活化水平升高。
WP9QY 功能化 PEG 水凝胶 (100 μM; 24 h) 可保护包埋的小鼠胰岛免受 50 ng/mL 人 TNFα 诱导的细胞凋亡及胰岛素分泌受损,维持细胞活力与功能。
WP9QY (10 μM; 72 h) 可抑制 50 μM 甲基汞在体外小鼠器官型脑切片中诱导的神经元细胞死亡。
WP9QY (100 μM; 14 d) 可通过糖胺聚糖基质积累显著增强 hMSC 二维培养体系中的软骨分化,该结果通过 Alcian Blue 染色 (MS-X37243) 及吸光度检测证实。
WP9QY (25-100 μM; 72 h) 可剂量依赖性地促进在维持培养基、软骨细胞分化培养基和成骨细胞分化培养基中培养的 hMSCs 的增殖,该结果通过 Hoechst 33342 (MS-L18348) 荧光检测证实。
WP9QY (100 μM; 14 d) 可在对照组及 RANKL 敲低的 C3H10T1/2 细胞中诱导软骨细胞分化,且不依赖于 RANKL 信号通路。
WP9QY (5-50 μM; 20 min) 可剂量依赖性地抑制 RAW 264.7 细胞中 RANKL 诱导的信号通路,不影响 M-CSF 诱导的信号通路。

Cell Viability Assay

Cell Line: differentiated rat adrenal pheochromocytoma (PC12) cells
Concentration: 100-250 μM WP9QY; 50 ng/mL human TNFα; 50 ng/mL 2.5S NGF
Incubation Time: 24 hours (TNFα exposure); 6 days (NGF differentiation)
Result: Maintained viability comparable to unchallenged cells in PEG-RGD-WP9QY hydrogels (100 μM and 250 μM WP9QY) under TNFα challenge.
Showed no significant increase in caspase 3/7 activity.
Confirmed minimal cell death via Live/Dead imaging.

Cell Differentiation Assay

Cell Line: human mesenchymal stem cells (hMSCs)
Concentration: 100 μM
Incubation Time: 14 days
Result: Increased absorbance at 620 nm to ~0.27, which was significantly higher than control's ~0.17 with p < 0.01.

Cell Differentiation Assay

Cell Line: mouse chondrogenic ATDC5 cells
Concentration: 25-100 μM
Incubation Time: 18 days
Result: Induced dose-dependent chondrocytic differentiation, with more intense Alcian Blue staining at 100 μM compared to 25 μM, and no staining in untreated control cells.

Cell Differentiation Assay

Cell Line: human mesenchymal stem cells (hMSCs)
Concentration: 50-150 μM (with 10 ng/mL TGF-β3 present throughout culture)
Incubation Time: 14 days
Result: Induced dose-dependent enlargement of hMSC 3D pellets, with larger pellets observed at 150 μM compared to 50 μM.
Increased Alcian Blue-positive cartilage matrix production in treated pellets.

Cell Differentiation Assay

Cell Line: human mesenchymal stem cells (hMSCs)
Concentration: 100 μM (tested alone and in combination with 20 ng/mL TGF-β3)
Incubation Time: 15 days
Result: Strongly enhanced chondrogenesis alone, while TGF-β3 alone weakly enhanced chondrogenesis.
Combined treatment resulted in synergistically increased Alcian Blue staining intensity, showing greater chondrogenesis than either treatment alone.

Cell Differentiation Assay

Cell Line: human mesenchymal stem cells (hMSCs)
Concentration: 100 μM (tested alone and in combination with 10 ng/mL TGF-β3)
Incubation Time: 21 days
Result: Increased pellet size and induced cartilage matrix production (positive Alcian Blue and Safranin O staining) alone.
TGF-β3 alone increased chondrocytic differentiation but did not affect pellet size.
Combined treatment resulted in synergistically enhanced cartilage matrix production and larger pellet size compared to either treatment alone.

Cell Proliferation Assay

Cell Line: human mesenchymal stem cells (hMSCs)
Concentration: 25-100 μM
Incubation Time: 72 hours
Result: Promoted hMSC proliferation in maintenance, chondrocyte-differentiation, and osteoblast-differentiation media in a dose-dependent manner.
Elevated fluorescence intensity at 25 μM compared to untreated controls; further increased intensity at 100 μM, with p < 0.01 for all comparisons to untreated controls.

Cell Differentiation Assay

Cell Line: mouse mesenchymal C3H10T1/2 cells (control and RANKL-knockdown)
Concentration: 100 μM
Incubation Time: 14 days
Result: Enhanced chondrocytic differentiation (positive Alcian Blue staining) in both control and RANKL-knockdown C3H10T1/2 cells.
RANKL knockdown had no effect on WP9QY-induced chondrogenesis.
体内研究
(In Vivo)

WP9QY (5 mg;关节腔内注射;2 次 (第 14 天和第 21 天)) 可显著改善兔全层关节软骨缺损的修复效果,表现为改良 Wakitani 评分降低。
WP9QY (2.1 mg/kg/d;通过渗透微型泵持续输注;4 周) 可完全预防雌性 C57BL/6J 小鼠卵巢切除诱导的骨质疏松症,将松质骨参数恢复至假手术水平,并将破骨细胞活性降低至接近假手术水平。
WP9QY (9 mg/kg;皮下注射;每 3 小时 1 次;持续 48 h) 可完全预防雄性 CD-1 小鼠由低钙饮食诱导的骨质疏松症,将松质骨参数恢复至接近正常钙饮食水平,并将破骨细胞活性降低至接近正常钙饮食水平。
WP9QY (4 mg/kg/d;通过渗透微型泵持续输注;7 天) 可完全预防低膳食 Ca2+ 诱导的 TNFR (I)-/- TNFR (II)-/- 小鼠和野生型小鼠骨质疏松。

Animal Model: Japanese white (male, 19-20 weeks old)
Dosage: 5 mg
Administration: intraarticular; 2 doses (days 14 and 21)
Result: Caused partial filling of articular cartilage defects and expanded Safranin-O-positive regions in defects.
Reduced mean modified Wakitani score to ~7, versus ~12 for vehicle (P=0.04).
Animal Model: C57BL/6J Mice (female, 12 weeks old, bilateral ovariectomy-induced)
Dosage: 2.1 mg/kg/d
Administration: continuous infusion via osmotic minipump; 4 weeks
Result: Maintained bone mineral density of proximal tibiae at levels not significantly different from sham-operated mice.
Restored cancellous bone volume fraction from 9.10% to 14.79%.
Restored trabecular number from 6.10 no./mm to 8.01 no./mm.
Restored trabecular spacing from 150.12 μm to 109.998 μm.
Reduced osteoclast number per bone surface from 7.62 no./mm to 3.65 no./mm.
Reduced osteoclast surface per bone surface from 11.58% to 5.96%.
Blocked the ovariectomy-induced increase in urinary deoxypyridinoline cross-links.
Had no effect on body weight or uterine weight.
Animal Model: TNFR(I)-/- TNFR(II)-/- Mice (129/B6 background); wild-type (genetically matched, low dietary calcium-induced)
Dosage: 4 mg/kg/d
Administration: continuous infusion via osmotic minipump; 7 days
Result: Maintained bone mineral density at levels not significantly different from mice on a normal-calcium diet in both TNFR double-knockout and wild-type mice.
Blocked the low-calcium diet-induced increase in urinary deoxypyridinoline cross-links in both genotypes.
性状 固体
颜色 White to off-white

化学信息

分子量 1226.38
分子式 C58H71N11O15S2
CAS No. 199999-60-5

储存&溶解度

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (81.54 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : 1 mg/mL (0.82 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM0.8154 mL4.0770 mL8.1541 mL20.3852 mL
5 mM0.1631 mL0.8154 mL1.6308 mL4.0770 mL
10 mM0.0815 mL0.4077 mL0.8154 mL2.0385 mL
15 mM0.0544 mL0.2718 mL0.5436 mL1.3590 mL
20 mM0.0408 mL0.2039 mL0.4077 mL1.0193 mL
25 mM0.0326 mL0.1631 mL0.3262 mL0.8154 mL
30 mM0.0272 mL0.1359 mL0.2718 mL0.6795 mL
40 mM0.0204 mL0.1019 mL0.2039 mL0.5096 mL
50 mM0.0163 mL0.0815 mL0.1631 mL0.4077 mL
60 mM0.0136 mL0.0680 mL0.1359 mL0.3398 mL
80 mM0.0102 mL0.0510 mL0.1019 mL0.2548 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础